• Overview of the Guideline
• Evaluation and treatment of Dyslipidemia Early
• New Therapeutic agents to treat dyslipidemia
• Use of PREVENT-ASCVD to personalize risk assessment
• Updated LDL-C and non-HDL-C treatment approaches
• Expanded use of ApoB and screening recommendations for Lp(a)
• Calcium scoring and risk refinement
• Familial hypercholesterolemia recognition
• Dyslipidemia management in women and pregnancy

Slide Deck – Dr. Isiadinso

Summary of Dr. Isiadinso’s Presentation

Putting the Guideline into Action: Implementation Strategies
Ann Marie Navar MD, PhD

• Addressing misinformation and statin reluctance, fears
• Addressing statin intolerance
• Increasing access to CAC testing
• How to raise awareness about Lp(a) testing, and cascade screening for that and FH
• Barriers to uptake of new non-statin therapies
• How to implement new guidelines in practice- clinical challenges and opportunities for innovation
• Beyond the doctor’s office- community and employer-based outreach
• Policy-level changes needed to facilitate guideline implementation
• What could success look like over the next five years?

Slide Deck – Dr. Navar

Summary of Dr. Navar’s Presentation

Read the Q&A and Open Forum

Closing Remarks and Next Steps